Related Experiment Video
Updated: Jun 22, 2026
04:57
Establishing a Competing Risk Regression Nomogram Model for Survival Data
Published on: October 23, 2020
Risk stratification for therapeutic management and prognosis
Otavio R Coelho-Filho1, Leelakrishna Nallamshetty, Raymond Y Kwong
1Brigham and Women's Hospital, Boston, MA 02115, USA.
Heart Failure Clinics
|July 1, 2009
Summary
Cardiac magnetic resonance (CMR) imaging offers comprehensive cardiac assessment, integrating multiple sequences for detailed anatomic, functional, and physiologic data. This makes CMR the preferred method for evaluating coronary artery disease and cardiomyopathies of unknown origin.
Area of Science:
- Cardiovascular Imaging
- Radiology
- Cardiac MRI
Background:
- Coronary artery disease (CAD) assessment often requires multiple imaging modalities.
- Cardiac magnetic resonance (CMR) integrates various pulse sequences for comprehensive cardiac evaluation.
- CMR is increasingly recognized for diagnosing cardiomyopathies of unknown cause.
Purpose of the Study:
- To review the prognostic role of CMR in coronary artery disease (CAD).
- To discuss CMR applications and prognostication in non-coronary cardiac conditions.
- To highlight CMR's utility in assessing complex cardiac pathologies.
Main Methods:
- Integration of multiple CMR pulse sequences: myocardial perfusion, cine wall motion, T2-weighted imaging, late gadolinium enhancement, and CMR angiography.
- Utilizing a single imaging session to gather diverse cardiac information.
- Reviewing existing evidence on CMR's prognostic value.
Main Results:
- CMR provides integrated anatomic, functional, and physiologic data in one session.
- Evidence supports CMR's prognosticating role in CAD.
- CMR is valuable for assessing non-coronary cardiac conditions.
Conclusions:
- CMR is a versatile tool for comprehensive cardiac assessment.
- Its ability to interrogate myocardial physiology makes it a leading diagnostic method.
- CMR plays a crucial role in managing patients with CAD and cardiomyopathies.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...